Cancer

Onco-Innovations Announces Closing of Private Placement

Not for distribution to United States wire services or for dissemination in the United States VANCOUVER, BC / ACCESS Newswire…

4 months ago

New Study from Caris Life Sciences Validates Optimal Sequencing in Informing Therapy Choices for Breast Cancer Subgroups

IRVING, Texas, Aug. 13, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision…

4 months ago

The Healthcare Businesswomen’s Association (HBA) Honors AstraZeneca and Viseven with 2025 ACE Awards for Workforce Innovation and Global Impact

The HBA's ACE Awards spotlight bold, people-first programs that are transforming how the industry develops, engages, and empowers its workforce.…

4 months ago

Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

Builds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer.Engineered for precision T-cell activation…

4 months ago

Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

Builds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer.Engineered for precision T-cell activation…

4 months ago

KIFFIK Biomedical Onboards Industry Leaders Rene Veloso and Dr. Reginald Swift to Expand Business and Clinical Operations

Rene Veloso, JD, MBA, joins KIFFIK to lead investor relations and secure new funding to fuel clinical operationsRubix Life Sciences…

4 months ago

KIFFIK Biomedical Onboards Industry Leaders Rene Veloso and Dr. Reginald Swift to Expand Business and Clinical Operations

Rene Veloso, JD, MBA, joins KIFFIK to lead investor relations and secure new funding to fuel clinical operationsRubix Life Sciences…

4 months ago

MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy

Cancer-fighting immunosuppressive agents shown to disrupt telomeres and suspend growth of cancer cells  CHICAGO , Aug. 13, 2025 (GLOBE NEWSWIRE)…

4 months ago

MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy

Cancer-fighting immunosuppressive agents shown to disrupt telomeres and suspend growth of cancer cells  CHICAGO , Aug. 13, 2025 (GLOBE NEWSWIRE)…

4 months ago

Dogwood Therapeutics Reports Second Quarter 2025 Financial Results

- Enrollment to-date of 52 patients in the ongoing Halneuron® Phase 2b Trial - - Halneuron® Chemotherapy-Induced Neuropathic Pain (“CINP”)…

4 months ago